Cefalonium

Cefalonium

SCHEMBL125252

NC(=O)c1cc[n+](CC2=C(C(=O)[O-])N3C(=O)[C@@H](NC(=O)Cc4cccs4)[C@H]3SC2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 12/20 1.00
HSD17B10 Q99714 7/20 1.00
LMNA P02545 5/20 1.00
MAPT P10636 8/20 0.83
KDM4E B2RXH2 5/20 0.83
HPGD P15428 4/20 0.83
KMT2A Q03164 4/20 0.83
MEN1 O00255 3/20 0.83
NR1I2 O75469 3/20 0.83
ALDH1A1 P00352 2/20 0.83
SLC22A6 Q4U2R8 2/20 0.83
SLC22A8 Q8TCC7 2/20 0.83
SLC22A11 Q9NSA0 2/20 0.83
ALOX15 P16050 1/20 0.83
RECQL P46063 1/20 0.83
PTGS1 P23219 1/20 0.83
POLB P06746 3/20 0.64
CYP3A4 P08684 2/20 0.64
APEX1 P27695 2/20 0.64
GLA P06280 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cefalonium SCHEMBL28323454 0.99 TDP1 (0.98) TDP1HSD17B10LMNAMAPTKDM4E
Cefalonium SCHEMBL28419781 0.99 TDP1 (0.98) TDP1HSD17B10LMNAMAPTKDM4E
Cefalonium SCHEMBL28172994 0.99 TDP1 (0.98) TDP1HSD17B10LMNAMAPTKDM4E
Cefalonium SCHEMBL28295839 0.98 TDP1 (0.95) TDP1HSD17B10LMNAMAPTKDM4E
Cefalonium SCHEMBL11187482 0.93 TDP1 (0.86) TDP1HSD17B10LMNAMAPTKDM4E
Cefalonium SCHEMBL11187484 0.93 TDP1 (0.86) TDP1HSD17B10LMNAMAPTKDM4E
Cephaloridine SCHEMBL3936 0.91 TDP1 (1.00) TDP1HSD17B10LMNAMAPTKDM4E
Cephaloridine SCHEMBL10665308 0.91 TDP1 (1.00) TDP1HSD17B10LMNAMAPTKDM4E
Cephaloridine SCHEMBL10665298 0.91 TDP1 (1.00) TDP1HSD17B10LMNAMAPTKDM4E
Cephaloridine SCHEMBL2908926 0.91 TDP1 (1.00) TDP1HSD17B10LMNAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3098 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637481-B2 Boronic acid derivatives and therapeutic uses thereof QPEX BIOPHARMA, INC. (US) 2026-05-26 US claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 US claimed
US-20250339551-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2025-11-06 US claimed
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-4642492-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
US-12371429-B2 Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof RECREO PHARMACEUTICALS LLC (US) 2025-07-29 US claimed
US-20250222118-A1 Beta-Lactam-Cannabinoid Conjugate Molecules DIVERSE BIOTECH INC (US) 2025-07-10 US claimed
US-12251417-B2 Antimicrobial compounds from the genus Delftia MINISTRY OF HEALTH, STATE OF ISRAEL (IL) 2025-03-18 US claimed
WO-2024240173-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2024-11-28 WO claimed
US-20040033938-A1 Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis PHARMACIA CORPORATION 2004-02-19 US claimed
EP-1372699-A1 METHOD OF IMPROVING THE GROWTH PERFORMANCE OF AN ANIMAL THE UNIVERSITY OF SYDNEY (AU) 2004-01-02 EP claimed
US-20030219461-A1 Parenteral combination therapy for infective conditions PHARMACIA CORPORATION 2003-11-27 US claimed
WO-2002096216-A1 A METHOD OF IMPROVING THE GROWTH PERFORMANCE OF AN ANIMAL THE UNIVERSITY OF SYDNEY (AU) 2002-12-05 WO claimed
WO-2002067979-A1 METHOD OF IMPROVING THE GROWTH PERFORMANCE OF AN ANIMAL THE UNIVERSITY OF SYDNEY (AU) 2002-09-06 WO claimed
US-5415867-A Complexes with cephalosporins as bactericides THE LIPOSOME COMPANY, INC. (US) 1995-05-16 US claimed
EP-0414806-B1 HIGH RATIO ACTIVE AGENT:LIPID COMPLEX LIPOSOME CO INC (US) 1994-07-20 EP claimed
EP-0414806-A4 HIGH RATIO ACTIVE AGENT:LIPID COMPLEX 1991-11-13 EP claimed
EP-0414806-A1 HIGH RATIO ACTIVE AGENT:LIPID COMPLEX. LIPOSOME CO INC (US) 1991-03-06 EP claimed
WO-1989011272-A1 HIGH RATIO ACTIVE AGENT:LIPID COMPLEX THE LIPOSOME COMPANY, INC. (US) 1989-11-30 WO claimed